Essen Biotech — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications1liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Drug Product is administered by IV infusion following myeloablative conditioning with busulfanThis study is an open-label, non-randomized, single-dose Phase 1/2 trial involving around 85 adult and pediatric participants aged between 2 and 50 years with sickle cell disease (SCD). It aims to assess the effectiveness of hematopoietic stem cell transplantation (HSCT) using BAH243 for SCD.	SEP	Phase 1/2	Thérapie cellulaire	China	À vérifier
Drug Product is administered by IV infusion following myeloablative conditioning with busulfanThis study is an open-label, non-randomized, single-dose Phase 1/2 trial involving around 85 adult and pediatric participants aged between 2 and 50 years with sickle cell disease (SCD). It aims to assess the effectiveness of hematopoietic stem cell transplantation (HSCT) using BAH243 for SCD.	SEP	Phase 1/2	Thérapie génique + Thérapie cellulaire	China	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Drug Product is administered by IV infusion following myeloablative conditioning with busulfan	SEP	Phase 1/2	NCT06399107	Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease	RECRUITING

Publications

1

Molécule	Indication / population	Titre	Journal	Date
Drug Product is administered by IV infusion following myeloablative conditioning with busulfan		A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.	Bone marrow transplantation